Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

EQRx, Inc. - Common Stock (NQ: EQRX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about EQRx, Inc. - Common Stock

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
From Kahn Swick & Foti, LLC
Via Business Wire
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
From Robbins LLP
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)
From Brodsky & Smith LLC
Via GlobeNewswire
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
From Kahn Swick & Foti, LLC
Via Business Wire
EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
From Revolution Medicines, Inc.; EQRx, Inc.
Via GlobeNewswire
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
From EQRx, Inc.
Via GlobeNewswire
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
From EQRx, Inc.
Via GlobeNewswire
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
From Robbins LLP
Via Business Wire
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
From EQRx, Inc.
Via GlobeNewswire
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From EQRx, Inc.
Via GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
From EQRx, Inc.
Via GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
From EQRx, Inc.
Via GlobeNewswire
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
From EQRx, Inc.
Via GlobeNewswire
EQRx to Participate in the Jefferies 2022 London Healthcare Conference
From EQRx, Inc.
Via GlobeNewswire
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
From EQRx, Inc.
Via GlobeNewswire
EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022
From Eqrx, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.